These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8721333)

  • 1. Role of tissue inhibitors of metalloproteinase in diabetic nephropathy.
    Kanauchi M; Nishioka H; Nakashima Y; Hashimoto T; Dohi K
    Nihon Jinzo Gakkai Shi; 1996 Mar; 38(3):124-8. PubMed ID: 8721333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic significance of urinary fibronectin in diabetic nephropathy.
    Kanauchi M; Nishioka H; Dohi K
    Nihon Jinzo Gakkai Shi; 1995 Feb; 37(2):127-33. PubMed ID: 7752504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic significance of urinary transferrin in diabetic nephropathy.
    Kanauchi M; Nishioka H; Hashimoto T; Dohi K
    Nihon Jinzo Gakkai Shi; 1995 Nov; 37(11):649-54. PubMed ID: 8583702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic significance of urinary immunoglobulin G in diabetic nephropathy].
    Yashima I; Hirayama T; Shiiki H; Kanauchi M; Dohi K
    Nihon Jinzo Gakkai Shi; 1999 Dec; 41(8):787-96. PubMed ID: 10655727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic significance of urinary sialic acid in diabetic nephropathy.
    Takenaka Y; Kanauchi M; Dohi Y; Dohi K; Ishikawa H
    Nihon Jinzo Gakkai Shi; 1992 Jan; 34(1):85-90. PubMed ID: 1593801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
    Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis.
    Akiyama K; Shikata K; Sugimoto H; Matsuda M; Shikata Y; Fujimoto N; Obata K; Matsui H; Makino H
    Res Commun Mol Pathol Pharmacol; 1997 Feb; 95(2):115-28. PubMed ID: 9090749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis.
    Sanders JS; Huitema MG; Hanemaaijer R; van Goor H; Kallenberg CG; Stegeman CA
    Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1927-34. PubMed ID: 17898039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
    Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
    Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
    Ishiguro N; Ito T; Obata K; Fujimoto N; Iwata H
    J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum and urinary type IV collagen concentrations in the assessment of diabetic microangiopathy.
    Banu N; Hara H; Egusa G; Yamakido M
    Hiroshima J Med Sci; 1994 Dec; 43(4):123-33. PubMed ID: 7883578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy.
    Suzuki D; Miyazaki M; Jinde K; Koji T; Yagame M; Endoh M; Nomoto Y; Sakai H
    Kidney Int; 1997 Jul; 52(1):111-9. PubMed ID: 9211353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical implications of urine matrix metalloproteinases and their inhibitors in patients with chronic glomerulonephritis].
    Li OA; Bobkova IN; Kozlovckaia LV
    Ter Arkh; 2009; 81(8):10-4. PubMed ID: 19799193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
    Terada T; Okada Y; Nakanuma Y
    Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients.
    Navarro JF; Mora C; Muros M; García J
    Nephrol Dial Transplant; 2006 Dec; 21(12):3428-34. PubMed ID: 16935891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
    McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
    Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor-alpha, -beta in human diabetic nephropathy.
    Uehara G; Suzuki D; Toyoda M; Umezono T; Sakai H
    Clin Exp Nephrol; 2004 Mar; 8(1):36-42. PubMed ID: 15067514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.
    Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H
    Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.